Analystreport

Blueprint Medicines Co. (NASDAQ: BPMC) had its price target lowered by analysts at Morgan Stanley from $105.00 to $101.00. They now have an "equal weight" rating on

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com